Revvity Develops High-Throughput T-SPOT.TB Automated Platform for Clinical Labs
Revvity, Inc. has announced the development of the T-SPOT™ A201, a high-throughput automated platform aimed at enhancing the performance and efficiency of T-SPOT.TB™ testing for large-volume clinical laboratories. This innovative platform addresses the ongoing global health challenge posed by tuberculosis and meets the increasing testing demands from immigration screening and pre-treatment evaluations for immunosuppressive therapies.
WALTHAM, Mass.–(BUSINESS WIRE)–Revvity, Inc. today announced the development of the T-SPOT™ A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB™ testing for large-volume clinical labs, enabling a reliable, accurate solution for latent tuberculosis (TB) detection. Tuberculosis remains a critical global health challenge, with testing demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies